NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.84 by $0.01. The medical research company earned $701.80 million during the quarter, compared to the consensus estimate of $694.73 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. The firm's revenue was up 43.9% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

10 analysts have issued 12-month price objectives for PRA Health Sciences' stock. Their predictions range from $86.00 to $115.00. On average, they anticipate PRA Health Sciences' stock price to reach $97.80 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Ratings for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

PRA Health Sciences saw a decline in short interest in June. As of June 29th, there was short interest totalling 2,898,254 shares, a decline of 31.5% from the June 15th total of 4,229,589 shares. Based on an average daily volume of 1,135,267 shares, the short-interest ratio is presently 2.6 days. Currently, 4.5% of the shares of the stock are sold short. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Media coverage about PRAH stock has trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PRA Health Sciences earned a news sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 46.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.48%), Scout Investments Inc. (0.12%), Fred Alger Management Inc. (0.10%), Bellecapital International Ltd. (0.10%), Retirement Systems of Alabama (0.10%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, NN Investment Partners Holdings N.V. and Scout Investments Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bellecapital International Ltd., Louisiana State Employees Retirement System, Municipal Employees Retirement System of Michigan, First National Bank of Hutchinson, State of Alaska Department of Revenue, Amalgamated Bank and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $102.52.

PRA Health Sciences has a market capitalization of $6.57 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]